EMA panel rejects Biogen Alzheimer’s drug

A European regulatory panel has voted against approval of Biogen Inc’s Alzheimer’s disease drug, in a possible blow to the prospects of the drug already grappling with a slow rollout in the United States.

Shares of the US-based company were down 3.6 per cent before the bell, after it announced…